Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis.

UNLABELLED Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. BACKGROUND SPARC has been implicated as a counteradhesive and antiproliferative protein associated with deposits of extracellular matrix in renal disease. METHOD We have examined the effect of recombinant SPARC containing a C-terminal His tag (rSPARC) in an acute model of mesangial cell injury that is induced in the rat by an antibody against the Thy1 antigen on the mesangial cell membrane. The recombinant protein was administered 24 hours after the induction of nephritis and was infused through day 4. RESULTS rSPARC was localized to the renal glomeruli of rats treated with anti-Thy1 antibody. Type I collagen and fibronectin, as well as transforming growth factor-beta1 (TGF-beta1), were increased at day 5 in rats treated with rSPARC (N = 4, P < 0.05 vs. delivery buffer), but only minimal effects were seen on mesangial cell and endothelial cell proliferation. In primary cultures of rat mesangial cells, infusion of rSPARC was associated with increases in TGF-beta1 mRNA and in total, secreted TGF-beta1 protein. CONCLUSIONS rSPARC stimulates expression of TGF-beta1 both in vitro and in vivo. Given the closely regulated expression of SPARC, TGF-beta1, and type I collagen in several animal models of glomerulonephritis, we propose that SPARC could be one of the major mediators of the induction of TGF-beta1 in renal disease.

[1]  E. Sage,et al.  Cell cycle‐dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix , 1999, Journal of cellular biochemistry.

[2]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[3]  W. Couser,et al.  Anti-vitronectin antibodies enhance anti-Thy-1-induced proteinuria in PVG/c, but not in Wistar rats. , 1998, Journal of the American Society of Nephrology : JASN.

[4]  W. Couser,et al.  Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. , 1998, Kidney international.

[5]  W. Kriz,et al.  Synaptopodin: An Actin-associated Protein in Telencephalic Dendrites and Renal Podocytes , 1997, The Journal of cell biology.

[6]  S. E. Thomas,et al.  Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. , 1997, Kidney international.

[7]  R. Timpl,et al.  Crystal structure of a pair of follistatin‐like and EF‐hand calcium‐binding domains in BM‐40 , 1997, The EMBO journal.

[8]  R. Timpl,et al.  Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). , 1997, The Biochemical journal.

[9]  H. Lodish,et al.  Biosynthesis of the type I and type II TGF-beta receptors. Implications for complex formation. , 1997, The Journal of biological chemistry.

[10]  D. Rifkin,et al.  Latent Transforming Growth Factor-β Binding Protein Domains Involved in Activation and Transglutaminase-dependent Cross-Linking of Latent Transforming Growth Factor-β , 1997, The Journal of cell biology.

[11]  M. Reed,et al.  SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. , 1996, Kidney international.

[12]  R. Jaenisch,et al.  Type I collagen‐deficient Mov‐13 mice do not retain SPARC in the extracellular matrix: Implications for fibroblast function , 1996, Developmental dynamics : an official publication of the American Association of Anatomists.

[13]  E. Sage,et al.  Renaturation of SPARC expressed in Escherichia coli requires isomerization of disulfide bonds for recovery of biological activity. , 1996, The international journal of biochemistry & cell biology.

[14]  W. Kriz.  Progressive renal failure--inability of podocytes to replicate and the consequences for development of glomerulosclerosis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  S. Friedman,et al.  Differential expression of transforming growth factor-β isoforms and receptors in experimental membranous nephropathy , 1996 .

[16]  W. Couser,et al.  The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. , 1996, The Journal of clinical investigation.

[17]  M. Reed,et al.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. , 1996, The American journal of pathology.

[18]  C. Alpers,et al.  Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. , 1996, Kidney international.

[19]  P. Porter,et al.  Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. , 1996, The Journal of clinical investigation.

[20]  R. Timpl,et al.  Structure of a novel extracellular Ca2+-binding module in BM-40 , 1996, Nature Structural Biology.

[21]  W. Couser,et al.  Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. , 1995, Kidney international.

[22]  R. Timpl,et al.  Two Adjacent N-terminal Glutamines of BM-40 (Osteonectin, SPARC) Act as Amine Acceptor Sites in TransglutaminaseC-catalyzed Modification (*) , 1995, The Journal of Biological Chemistry.

[23]  G. Jerums,et al.  SPARC gene expression is reduced in early diabetes-related kidney growth. , 1995, Kidney international.

[24]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[25]  N. Ling,et al.  The heparin binding site of follistatin is involved in its interaction with activin. , 1995, Biochemical and biophysical research communications.

[26]  E. Sage,et al.  SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin‐like region and the Ca2+‐binding EF‐hand , 1995, Journal of cellular biochemistry.

[27]  M. Folkman,et al.  Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca2+‐binding EF‐hand sequence , 1995, Journal of cellular biochemistry.

[28]  X. Ding,et al.  SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Yamamoto,et al.  Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. , 1994, Kidney international.

[30]  E. Sage,et al.  The biology of SPARC, a protein that modulates cell‐matrix interactions , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  E. Sage,et al.  Specific interaction of SPARC with endothelial cells is mediated through a carboxyl-terminal sequence containing a calcium-binding EF hand. , 1993, The Journal of biological chemistry.

[32]  Y. Kaneda,et al.  Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. , 1993, The Journal of clinical investigation.

[33]  D. Rifkin,et al.  Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells , 1993, The Journal of cell biology.

[34]  W. Couser,et al.  Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. , 1993, Kidney international.

[35]  E. Ruoslahti,et al.  Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.

[36]  C. Alpers,et al.  Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[37]  M. Iruela-Arispe,et al.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.

[38]  C. Alpers,et al.  Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor , 1992, The Journal of experimental medicine.

[39]  H. van Goor,et al.  Antibodies defining rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[40]  C. Alpers,et al.  Increased synthesis of extracellular matrix in mesangial proliferative nephritis. , 1991, Kidney international.

[41]  P. Bornstein,et al.  Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. , 1991, The Journal of biological chemistry.

[42]  E. Sage,et al.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Sage,et al.  Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape , 1990, The Journal of cell biology.

[44]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[45]  M. Sporn,et al.  Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.

[46]  M. Sporn,et al.  Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in culture , 1989 .

[47]  H. Abboud,et al.  Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. , 1988, The American journal of physiology.

[48]  T. Yamamoto,et al.  Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. , 1987, Kidney international.

[49]  W. Couser,et al.  Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. , 1986, The Journal of clinical investigation.

[50]  P. Bornstein,et al.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.

[51]  N. Young,et al.  An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. , 1972, The Journal of clinical investigation.

[52]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[53]  E. Sage,et al.  Expression of biologically active human SPARC in Escherichia coli. , 1996, Archives of biochemistry and biophysics.

[54]  W. Couser,et al.  Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? , 1994, Kidney international. Supplement.

[55]  W. Border,et al.  Transforming growth factor-beta and the pathogenesis of glomerular diseases. , 1994, Current opinion in nephrology and hypertension.

[56]  D. Salant,et al.  Expression of type I collagen mRNA in glomeruli of rats with passive Heymann nephritis. , 1993, Kidney international.

[57]  E. Engvall,et al.  Fibronectin: purification, immunochemical properties, and biological activities. , 1982, Methods in enzymology.